Not that I'm one to side with Snoopy's general viewpoint but there is merit in buying on the way down, at least for a fundamental/value investor.
Printable View
...and if you don't fit that then here's some more ...
http://www.pacificedge.co.nz/about-u...e-?stage=Stage
http://www.pacificedge.co.nz/about-u...st?stage=Stage
Now, I don't want to be accused of "ramping up" (or to be so daring to suggest confidence that things might be starting to build in this great little company), so in a nice quiet voice I will simply say "the evidence appears to suggest the desired track towards sales may be starting to get worn a tiny wee bit".
As for sales....I definitely know they have received $320 in this current financial year. Ooopps ... sorry, didn't mean to get ahead of myself and start "ramping up".
For the non-medical types like me, this is probably the best takeaway right?
"These markers were then used to develop an optimized commercial test, which was significantly better than cytology as well as nuclear matrix protein 22 BladderChek and enzyme-linked immunosorbent assay tests..."
And for another non-medical type like me, this is also a wee takeaway too:
as this is one of the 'approaches' they are taking isn't it Mr Magoo?Quote:
a role in risk stratification of patients
This isn't new but I hadn't seen it. Includes a little more commentary on the adoption of CXbladder by BOP and Lakes District DHBs, and a mention of Peter Leitch using it which I hadn't come across before.
http://www.nzdoctor.co.nz/un-doctore...cxbladder.aspx (11 Feb 2014)
I think Hancocks is inferring that, given time and due process, we might be staring at the new gold standard?
woo hoo
but then, what would I know.....
Im sure Hancocks will set us all straight on this one. My understanding is that it was designed as an adjunct to the gold standard, cystoscopy, especially with its potential for discovering upper tract carcinoma. Whether it takes over as gold standard by default remains to be seen.